Did you know?
ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.
Free Newsletter
Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!
Free Report
Yesterday, Lilly held the official opening of its...
Jiangsu Hengrui Medicine has in-licensed China rights to...
Golden Meditech, a Beijing medical device company, will...
Chindex accepted a buy-out offer of $24 per share from...
Jiangsu Hengrui Medicine received CFDA permission to...
Shenzhen Hepalink Pharma, a heparin API company, will...
Jiangsu Hengrui Medicine announced plans to spend $137...
Jiangsu Hengrui Medicine will invest $240 million to...
MabSpace Biosciences, a Suzhou antibody company, raised...
Jiangsu Hansoh Pharma is planning a $3 billion Hong Kong...
ChinaBio® News
Greg Scott Interviewed at BIO-Europe Spring
How to bring your China assets to China in 8 minutes
"Mr. Bio in China."
Mendelspod Interview
Multinational pharma held to a higher standard in China
